Search
for
Sort by
Research 601–630 of 1000+
- Alopecia Areata: Clinical Treatment
- JAK1 gain-of-function variant causes alopecia areata, atopic dermatitis, and autoimmune thyroid disease
- Case Report: Vitiligo and Alopecia Universalis Following Rituximab Therapy in a Patient with Myasthenia Gravis
- Concomitant Alopecia Areata and Profound Bone Marrow Suppression: An Unusual Manifestation of Azathioprine Toxicity
- Gloriosa superba Poisoning-induced Anagen Effluvium
- Case Report: Baricitinib improved alopecia areata in a pediatric patient with atopic dermatitis
- Alopecia universalis following human papillomavirus vaccine administration: a case report
- Real‐life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24‐week Italian study
- Superficial Cryotherapy, Does It Work In Alopecia Areata?
- Alopecia Areata Mimicking Frontal Fibrosing Alopecia
- Drug-induced Telogen Effluvium in a Pediatric Patient due to Error of Transcription.
- Janus kinase inhibitors for alopecia areata: A narrative review
- Frontal Fibrosing Alopecia in Men: A Review of the Literature
- Frontal Fibrosing Alopecia: A Comprehensive Review with Recent Updates
- Tyrosine kinase Inhibitors in Dermatology: A Systemic Review
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- Alopecia Areata: An Evidence-Based Treatment Update
- Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia
- Assessment and Treatment Outcomes of Persistent Radiation-Induced Alopecia in Patients With Cancer
- Utilities of Botulinum Toxins in Dermatology and Cosmetology
- Alopecia areata: Part 2: treatment.
- Clinical Presentations and Comorbidities of Pediatric Alopecia Areata
- Prevention and Treatment of Chemotherapy-Induced Alopecia: What Is Available and What Is Coming?
- SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata
- Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
- Utility of trichoscopy in comparison to the standard methods for assessing the disease activity, severity, and therapeutic response in alopecia areata
- Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs
- New Modalities in the Treatment of Refractory Alopecia Areata